Literature DB >> 25780871

Better risk assessment for individual substances.

Roland W Freudenmann, Ninja Freudenmann, Bartosz Zurowski, Carlos Schönfeldt-Lecuona, Bernhard J Connemann, Maximilian Gahr.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25780871      PMCID： PMC4353870          DOI： 10.3238/arztebl.2015.0120a

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate.

Authors:  Alison Diaper; Ann S Rich; Sue J Wilson; Kevin Craig; Colin T Dourish; Gerry R Dawson; David J Nutt; Jayne E Bailey
Journal:  Hum Psychopharmacol       Date:  2013-11       Impact factor: 1.672

2.  Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder.

Authors:  Timothy E Wilens; Paul G Hammerness; Joseph Biederman; Anne Kwon; Thomas J Spencer; Sarah Clark; Megan Scott; Amy Podolski; Jeffrey W Ditterline; Matthew C Morris; Hadley Moore
Journal:  J Clin Psychiatry       Date:  2005-02       Impact factor: 4.384

Review 3.  Treatment resistant hypertension--investigation and conservative management.

Authors:  Franz Weber; Manfred Anlauf
Journal:  Dtsch Arztebl Int       Date:  2014-06-20       Impact factor: 5.594

4.  Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.

Authors:  Teresa A Pigott; Apurva Prakash; Lesley M Arnold; Scott T Aaronson; Craig H Mallinckrodt; Madelaine M Wohlreich
Journal:  Curr Med Res Opin       Date:  2007-04-27       Impact factor: 2.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.